Mantle cell lymphoma: a
Immunotherapy after chemotherapy prolongs
Patient Survival (NEJM)
The addition of immunotherapy by rituximab after chemotherapy in patients
With mantle cell lymphoma has made it possible to prolong their survival, according to a
Study conducted by the French and Belgian centres of the Lymphoma study Association
(LYSA) and published on Wednesday in the New England Journal of Medicine (NEJM) 1
.
In this study of 299 patients with cell lymphoma
Coat and aged under 66 years at the time of diagnosis, half of the patients
Having been treated with chemotherapy, then an autologous stem cell transplant
Had received immunotherapy in the form of an injection of
Rituximab (a monoclonal anti-CD20 antibody) every two months for three years in
Day Hospital.
Four years after the end of chemotherapy, 89% of patients in this group were
Still alive, compared with 80% in the observation group that had not followed a
Immunotherapy.
We show with this study that immunotherapy therapy can delay
The occurrence of a relapse and prolong the survival of the patients. This is one more step in the
The process of combating this cancer which unfortunately still has a high risk of
Relapse, "says the principal investigator of the study, Prof. Steven le Gouill, hematologist
At the CHU de Nantes and member of the LYSA, a co-operator grouping 500
Researchers from 120 centres in Europe.
A new therapeutic strategy
"It is clear that the use of rituximab in maintenance after chemotherapy in this type of
Lymphoma will become a new standard of treatment so it is very
Likely to change in the treatment strategy for these patients.
Especially since we were able to reduce the chemotherapy protocol, which was alleviated, because of the
followed by a maintenance treatment, stresses Prof. Le Gouill.
1 S. The Gouill et al., Rituximab after autologous Stem-cell transplant in Mantle-cell Lymphoma, N Engl J Med 2017;
377:1250-60.
Lymphomas are blood cancers developing in the lymphatic tissue. It
This is the sixth most common type of cancer in France every year.
Mantle cell lymphoma is a rare form of lymphoma (6% of
Non-Hodgkin's lymphoma). It develops from B lymphocytes in an area
Glands, called the mantle area, where the cancer cells are located, hence the
His name.
It is almost incurable with a median of survival, all patients of all ages
40 months.
About lymphoma
Lymphomas are cancers of the lymphatic system. They represent the most hemopathy malignant
Almost half of all blood cancers. These are heterogeneous diseases, with more than 50
Lymphoma subtypes, which makes diagnosis difficult and requires different supports.
They are divided into about 80% of non-Hodgkin's lymphomas (NHL) and 20% of lymphomas
Hodgkin (LH). Lymphomas can affect all ages (including in children), are
Mainly ganglion but can touch (only or accompanying) all
Organs. There is no prevention or screening. Incidence has doubled in 30 years, with 14,000 new cases in
The LYSA is an association law 1901 working internationally, for clinical research against the
Lymphoma, the 6th most common cancer in Europe. Co-operator GROUP by the National Institute of
of cancer (INCa) in November 2012, it ratified the Charter of Independence of the co-operative groups in
Oncology. It federates a set of 500 researchers in 120 care centres in France and Europe
Around the management of patients with lymphoma, from diagnosis to patient follow-up
Healed. The group carries out projects since the first administration to humans of new treatments
To the establishment of therapeutic reference strategies. He collaborates with many teams
Scientists to understand and treat lymphomas, including the Institut Carnot CALYM
(Consortium for the acceleration of innovation and its transfer in the field of lymphoma), of which
He's a member. With a structure of clinical research and platforms of pathology, biology and
Imaging, it offers a complete and multidisciplinary expertise.
0 komentar:
Posting Komentar